Rethinking treatment paradigms for the deployment of SARS-CoV-2 antiviral drugs on the shifting landscape of new variants

Front Microbiol. 2022 Oct 12:13:998287. doi: 10.3389/fmicb.2022.998287. eCollection 2022.

¹ HIV/AIDS Unit, Infectious Diseases Division, Geneva University Hospitals, Geneva, Switzerland.
² Centre of Excellence in Long-acting Therapeutics (CELT), University of Liverpool, Liverpool, United Kingdom.
³ COVID Response and Pandemic Preparedness Director, Drugs for Neglected Diseases Initiative (DNDi), Geneva, Switzerland.
⁴ Strategy, Unitaid, Geneva, Switzerland.
⁵ Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital, Oslo, Norway.

No abstract available

Keywords: COVID-19; direct-acting antivirals; immunocompromised; monoclonal antibodies; omicron; resistance; variant emergence; variants.